Biotest AG

BIO3

DE0005227235

Pharmaceuticals

Market Closed - Xetra Other stock markets 11:36:21 2024-04-25 am EDT			5-day change	1st Jan Change
28.7 ^EUR	-0.69%		0.00%	-7.42%

Apr. 19	Biotest Launches New Plasma Collection Center in Germany	MT
Mar. 28	Biotest Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Biotest AG Provides Earnings Guidance for the Year 2021

August 12, 2021 at 01:00 am EDT

Biotest AG provided earnings guidance for the year 2021. For financial year 2021, the Board of Management expects revenue growth in the mid-single-digit percentage range. Based on the aforementioned factors, the Board of Management expects LBIT to be between EUR 5 million and EUR 10 million.

Latest news about Biotest AG

Biotest Launches New Plasma Collection Center in Germany	Apr. 19	MT
Biotest Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Biotest Aktiengesellschaft Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024	23-10-05	CI
Biotest Aktiengesellschaft Raises Earnings Guidance for the Year 2023	23-10-05	CI
Biotest Treats First Patient with Severe Community- Acquired Pneumonia in Phase III Trial with Trimodulin	23-09-12	CI
Biotest AG Announces US Food and Drug Administration Accepts Marketing Authorization Application for Immunoglobulin Yimmugo	23-09-07	CI
Biotest Aktiengesellschaft Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Biotest Aktiengesellschaft Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Biotest's Hyperimmunoglobulin Cytotect® CP Receives Five Additional Marketing Authorisations in Europe	23-05-04	CI
Biotest AG Opens 12Th Plasma Collection Centre in Hungary	23-04-25	CI
Blood plasma specialist Biotest again expects operating loss	23-03-23	DP
Transcript : Biotest Aktiengesellschaft, 2022 Earnings Call, Mar 23, 2023	23-03-23
Biotest Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
Biotest Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023	23-02-10	CI
Biotest Names New CFO	23-02-10	MT
Biotest Begins Study of Cytotect CP in Treatment of Cytomegalovirus Infections After Transplantation	23-01-24	MT
Biotest Aktiengesellschaft Treats First Covid-19 Patients with Trimodulin in TRICOVID Phase III Trial	23-01-09	CI
Germany's Biotest Recruits First Patient in Early-Stage Trial of Chronic Hepatitis B Treatment	22-12-08	MT
Biotest Aktiengesellschaft Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Transcript : Biotest Aktiengesellschaft, Q3 2022 Earnings Call, Nov 14, 2022	22-11-14
Biotest Aktiengesellschaft Opens 12th Plasma Collection Centre in the Czech Republic	22-09-06	CI
Biotest Aktiengesellschaft Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Biotest AG Conducts Clinical Phase III Study PreCyssion with Cmv Hyperimmunoglobulin (Cytotect CP Biotest-) for the Prevention of CMV Infection in the Unborn Child in Germany	22-07-25	CI

Chart Biotest AG

Duration

Period

More charts

Company Profile

Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. It develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.

Sector

Pharmaceuticals

Calendar

2024-05-06 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Biotest AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

28.9 EUR

Average target price

37 EUR

Spread / Average Target

+28.03%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
BIOTEST AG	-7.42%	1.49B
CSL LIMITED	-2.86%	87.31B
SAMSUNG BIOLOGICS CO.,LTD.	+2.63%	40.86B
BIOGEN INC.	-22.94%	29.36B
UCB	+58.56%	24.49B
BIOMARIN PHARMACEUTICAL INC.	-14.10%	17.31B
INCYTE CORPORATION	-18.95%	11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.61%	11.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.02%	11.26B
SWEDISH ORPHAN BIOVITRUM AB	+5.17%	8.31B

Biopharmaceuticals

Biotest AG

Equities

BIO3

DE0005227235

Pharmaceuticals

Biotest AG Provides Earnings Guidance for the Year 2021

Latest news about Biotest AG

Chart Biotest AG

Company Profile

Income Statement Evolution

Ratings for Biotest AG

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals